News for Neurotech International Limited (NTI.AX)

Chalmers’ $49b budget slumpHigher spending and lower company tax revenue will push the budget into a deeper deficit this financial year, according to economists at Deloitte who forecast Treasurer Jim

The ASX200 is set to open three quarters of a percent higher today despite US markets responding to comments from Jerome Powell

The ASX200 has closed 0.67% lower at 8,150 points. Investors have rising concerns about the Middle Eastern conflict.

Apr 17, 2024 / 02:00AM GMTMatthew Wright - NWR Communications - Moderator Hello, and welcome to this Neurotech investor webinar discussing three key announcemen

Neurotech International has attained a new milestone in its clinical trial for Autism Spectrum Disorder (ASD)

Jul 26, 2023 / 01:00AM GMTOperator Thank you for standing by, and welcome to the Neurotech International quarterly investor conference call. (Operator Instructi

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to detect autism and ADHD. It’s listing on the ASX next Thursday (April 4) under the code BB1. BlinkLab’s development is being led by chair Brian Leedman - a founder of ResApp Health - the cough analysis app sold to Pfizer two years ago in a $179 million deal.

Futures point to the ASX opening fairly flat this morning on another busy day of reporting.

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on progress of its lead candidate cannabinoid-based drug NTI164 to treat several paediatric neurological disorders where there is an unmet medical need for safe and effective therapies.

Specialist biopharmaceutical development company Neurotech International (ASX: NTI) has obtained critical approval to undergo testing of a potential treatment for Rett Syndrome, a disease that mainly affects female sufferers.

On Stockhead today, Taylor Collison is backing Genetic Signatures (ASX:GSS) to Outperform saying the medtech's PT could triple.

The ASX 200 finished 0.89% higher, XEC Emerging Companies is up 1.26%, Vita Group's added 75% and Keating's had a memory lapse for the ages.

Twitter has become the first social media platform to give cannabis advertising the all-clear - in US states where weed is legal.

Cannabis: Top pot analysts forecast the Asian market could grow by at least 10 times to around US$120 million by 2026.

The ASX health sector is down more than 8% as 2022 comes to end but in signs of optimism for 2023, Morgans has a basket of stocks to watch.

A llok back at all the news and other fluff from the markets and elsewhere that you might have missed today.

Oregon Governor pardons 45,000 people and dispensaries see a 50% increase in transactions before 'Danksgiving'.

The best battery metals stocks so far in 2022, holiday stocks finally ready for a proper Aussie summer, and is it time to welcome Growth back?

A lazy look back at what happened on the ASX (and elsewhere) today. Read it. You'll like it. Honest.